Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 19,818 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eric Benevich sold 19,818 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the transaction, the insider now directly owns 40,778 shares in the company, valued at $5,438,154.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Eric Benevich also recently made the following trade(s):

• On Thursday, March 14th, Eric Benevich sold 75,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $139.38, for a total value of $10,453,500.00.

Neurocrine Biosciences Trading Down 0.5 %

Shares of NBIX stock opened at $132.54 on Friday. The stock has a 50 day moving average of $136.16 and a two-hundred day moving average of $126.85. Neurocrine Biosciences, Inc. has a 12 month low of $89.04 and a 12 month high of $148.37. The company has a market capitalization of $13.19 billion, a P/E ratio of 54.77 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. During the same quarter last year, the company earned $0.88 EPS. The company’s quarterly revenue was up 25.0% on a year-over-year basis. Sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NBIX shares. Mizuho upped their target price on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a research report on Thursday, February 8th. The Goldman Sachs Group increased their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a report on Thursday, January 25th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. Citigroup lowered their price objective on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a report on Thursday, February 8th. Finally, JPMorgan Chase & Co. increased their price objective on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average price target of $139.67.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds have recently modified their holdings of NBIX. Rice Hall James & Associates LLC lifted its position in shares of Neurocrine Biosciences by 195.5% in the 1st quarter. Rice Hall James & Associates LLC now owns 206,755 shares of the company’s stock worth $19,383,000 after acquiring an additional 136,782 shares during the period. HighTower Advisors LLC lifted its position in shares of Neurocrine Biosciences by 48.8% during the 1st quarter. HighTower Advisors LLC now owns 5,745 shares of the company’s stock worth $544,000 after buying an additional 1,883 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Neurocrine Biosciences by 27.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,150 shares of the company’s stock worth $296,000 after buying an additional 684 shares during the period. Acadian Asset Management LLC bought a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $27,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Neurocrine Biosciences by 39.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 417,604 shares of the company’s stock worth $39,148,000 after buying an additional 117,422 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.